ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Regulatory T cells in the immunotherapy of melanoma.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.Melanoma research · 2019Pooled it
- Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.BMC cancer · 2016Trial
- Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment.Frontiers in immunology · 2025Review
- Dysregulated brain regulatory T cells fail to control reactive gliosis following repeated antigen stimulation.iScience · 2023Article
- Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.Journal for immunotherapy of cancer · 2023Article
- Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.International journal of molecular sciences · 2023Review
- NABP2 as an oncogenic biomarker promotes hepatocellular carcinoma progression and metastasis.American journal of translational research · 2023Article
- Review
- Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- Tre2-Bub2-Cdc16 Family Proteins Based Nomogram Serve as a Promising Prognosis Predicting Model for Melanoma.Frontiers in oncology · 2020Article
- T cell pathology in skin inflammation.Seminars in immunopathology · 2019Review
- Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.Integrative cancer therapies · 2018Article
- Biomarkers for Immune Checkpoint Inhibitors in Melanoma.Frontiers in oncology · 2018Review
- Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.International journal of molecular sciences · 2017Review
- Article
- Empirical Modeling of Physiochemical Immune Response of Multilayer Zinc Oxide Nanomaterials under UV Exposure to Melanoma and Foreskin Fibroblasts.Scientific reports · 2017Article
- Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with melanoma are supposed to develop spontaneous immune responses against specific tumor antigens. However, several mechanisms contribute to the failure of tumor antigen-specific T cell responses, inducing immune escape. Importantly, immunosuppression mediated by regulatory T cells (Tregs) in tumor lesions is a dominant mechanism of tumor immune evasion. Based on this information, several therapies targeting Tregs such as cyclophosphamide, IL-2-based therapies, and antibodies against the surface molecular of Tregs have been developed. However, only some of these strategies showed clinical efficacy in patients with melanoma in spite of their success in shifting immune systems to antitumor responses in animal models. In the future, strategies specifically depleting local Tregs, inhibiting Treg migration to the tumor lesion, and Treg depletion in combination with other chemotherapies or immune modulation will hopefully bring benefits to melanoma patients.
Indexed as
Identifiers
26515336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.